Funding will accelerate development of a novel genomic approach to infectious disease diagnostics designed to combat antibiotic resistance
BOSTON, August 7, 2017 — Day Zero Diagnostics, Inc., an infectious disease diagnostic company using genome sequencing and machine learning to enable rapid and precise treatment, announced today the completion of a $3M Series Seed financing. Leading investors in the round include Golden Seeds, a national angel investing network that focuses on early stage businesses with significant female leadership, and Sands Capital Ventures, a venture capital fund with extensive experience in next generation sequencing and infectious disease diagnostics. Funds will be used to support prototype development of the Day Zero diagnostic platform.
"DZD is on a mission to change the way infectious disease diagnostics are done," said Jong Lee, CEO and a co-founder of Day Zero Diagnostics. "We are extremely grateful to have a set of seed round investors who share in our vision and will act as partners in our early technical development."
The problem of antibiotic resistance has made rapid diagnostic information critical in the treatment of patients with a severe infection. DZD takes advantage of advances in high throughput sequencing and machine learning to take a big data approach to infectious disease identification and antibiotic susceptibility profiling, providing the information required to select a targeted therapy in hours rather than days.
As part of the financing, Laura Davis, PhD, a Managing Director at Golden Seeds and Michael Rubin, MD, Managing Partner of Sands Capital Ventures will join the Board of Directors. Jeff Mirviss, a member of the Executive Committee at Boston Scientific will also join as an independent member of the Board.
"We are pleased to partner with the team at Day Zero Diagnostics," said Michael Rubin, MD of Sands Capital Ventures. "The opportunity DZD is addressing is global in scope and increasingly pressing. In an environment where antibiotic resistance is proliferating, and broad spectrum antibiotics are heavily prescribed, DZD's innovative approach has the potential to markedly improve decision making."